SEC Form 4/A · accession 0001179110-16-023077
OSIRIS THERAPEUTICS, INC. · OSIR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jonathan Mark Hopper
Officer — Chief Medical Officer
Period of report
Apr 12, 2016
Accepted (ET)
Apr 15, 2016 · 7:43 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001360886
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $13.12 | Apr 12, 2016 | D | 6,250 | A | Nov 24, 2016 | Nov 24, 2024 | Common Stock | 6,250 | 18,750 | D |
| Incentive Stock Option (right to buy)F1 | $13.12 | Apr 12, 2016 | D | 6,250 | A | Nov 24, 2017 | Nov 24, 2024 | Common Stock | 6,250 | 12,500 | D |
| Incentive Stock Option (right to buy)F1 | $13.12 | Apr 12, 2016 | D | 6,250 | A | Nov 24, 2018 | Nov 24, 2024 | Common Stock | 6,250 | 6,250 | D |
Explanation of responses
- F1Unvested incentive stock option that were forfeited concurrent with the Reporting Person's separation from the company, consistent with the provisions of the Amended and Restated 2006 Omnibus Plan. The Reporting Person's stock options that were vested on the date that he separated from the company will remain exercisable for 90 days from the departure date.